CONTACT US   |  (864) 397-5101

SCbio Members Pitch Innovations To Global Investors, Experts at RESI 2024

A person standing in front of a group of people.

SCbio staff and its participating members traveled to Atlanta for the Redefining Early Stage Investments (RESI) conference series, which connects start-ups with early-stage investors and strategic channel partners. RESI maximizes company fundraising efforts to find partners who are a fit for their technology and stage of development.

SCbio members were featured in the conference’s Innovator Pitch Challenge (IPC), where early-stage life science and healthcare companies throughout the Southeast pitched directly to a panel of judges, featuring active investors and industry experts.

Lucie Medical Founder and CEO Jennifer West Cobb showed panelists how her company plans to improve maternal health globally with simple, cost-effective solutions to reduce excessive blood loss following childbirth with its maiden device, Kira. Kira is designed specifically for those undergoing cesarean delivery who are at a higher risk for postpartum hemorrhage. The Kira device is engineered to facilitate accurate assessment of blood loss in real-time, reduce the formation of intrauterine blood clots, and encourage physiologic contraction of the uterus thereby limiting the amount of blood loss during surgery.

Leukogene Founder and Chief Scientific Officer Nathan Dolloff explained the development of its first M2T product for acute myelogenous leukemia (AML). M2T is a recombinant protein-based platform that targets MHCII molecules and delivers tumor antigens to antigen-presenting cells for presentation to the immune system.

NeuroQuest shared its blood-based immunoassay, NeuroScreen™, which can predict the existence of beta amyloids in the brain with a 97% sensitivity and 88% specificity with an AUC of .93 at 15 CL. NeuroScreen™ is the only blood-based assay that does not rely on some species of tau protein and can identify asymptomatic individuals.

Precision Genetics Founder and CEO Nate Wilbourne pitched his value-based healthcare informatics company, powered by a molecular diagnostics database that improves patient outcomes while reducing the total care costs. Precision Genetics enables doctors to prescribe medications with precision and safety. Our solutions help provide better patient outcomes and lower overall healthcare costs.

SCbio President and CEO James Chappell joined other state bio association leaders on a panel where he shared his industry insights and SCbio’s latest programs and incentives to support life sciences companies, SCbioDrive and Main Street Labs.

In June, SCbio will represent the state at world’s largest industry gathering of biotechnology and biopharmaceutical leaders, the BIO International Convention in San Diego, California. To learn how you and your company can join the SC delegation, visit www.scbio.org.

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.